Sutro Biopharma, Inc. (STRO)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 11:19AM EDT. Market open.
| Previous Close | 3.7700 |
| Open | 3.7300 |
| Bid | 3.6800 x 200 |
| Ask | 3.7500 x 100 |
| Day's Range | 3.6900 - 3.8000 |
| 52 Week Range | 2.0100 - 6.1300 |
| Volume | |
| Avg. Volume | 1,011,385 |
| Market Cap | 285.376M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.89 |
Simply Wall St.Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by...
GlobeNewswireSutro Biopharma Announces Pricing of $75 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissi
GuruFocus.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
© 2024 Yahoo. All rights reserved.